New research reveals that individuals who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide may regain shed pounds far faster than those who stop conventional lifestyle programs.
Findings released in a prominent medical journal shows that while overweight individuals can lose a large proportion of their body weight while using the jabs, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals buying such drugs need to be cognizant of the danger of rapid weight regain when the medication is stopped," warns researcher Dr. Susan Jebb.
Such speed of recovery suggests a reversion to pre-treatment mass within about 18 months.
Weighing Treatments
The study, which examined 37 of trials involving over 9,000 of participants, contrasted the outcomes of the injectable medications with other pills.
The team note that individuals who shed pounds through diet and exercise usually have a more gradual creep back—approximately 0.1 kg a month—after stopping.
The Reason for the Fast Rebound
Experts believe the way of the jabs is key to understanding the amplified weight return.
These medications copy a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Artificially providing GLP-1 concentrations far above than normal could lead to the system to produce less of its own natural GLP-1, and could reduce sensitivity to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this hormone supplement results in hunger is uncontrolled, making overeating far more likely."
A Chronic Issue?
Health authorities advise the jabs for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
Professionals contend that, given the likelihood of relapse, the therapy might need to be ongoing.
This opinion is reinforced by drug manufacturers, who state that the results "emphasize the persistent nature of obesity," similar to managing conditions like diabetes.
User Accounts
Individuals who have come off the medication report a sudden resurgence of hunger.
"I experienced something flipping and I was suddenly extremely hungry," described an individual.
This difficulty is worsened if individuals have not adopted lasting lifestyle or habit modifications during treatment.
Significant Interest
Recent estimates suggest that millions of people in the UK have used weight-loss jabs in the past year, with interest remaining high.
- Adoption is greater among females compared to males.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
Finally, clinicians caution that while GLP-1 drugs are potent tools for shedding pounds, they are not a magic solution and long-term success likely depends on integrated lifestyle changes.
